Gilead Sciences (BUE:GILD) Current Accrued Expense : ARS1,372,522 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Current Accrued Expense?

Gilead Sciences's Current Accrued Expense for the quarter that ended in Dec. 2023 was ARS1,372,522 Mil.

Gilead Sciences's quarterly Current Accrued Expense increased from Jun. 2023 (ARS838,560 Mil) to Sep. 2023 (ARS1,299,714 Mil) and increased from Sep. 2023 (ARS1,299,714 Mil) to Dec. 2023 (ARS1,372,522 Mil).

Gilead Sciences's annual Current Accrued Expense declined from Dec. 2021 (ARS749,750 Mil) to Dec. 2022 (ARS583,254 Mil) but then increased from Dec. 2022 (ARS583,254 Mil) to Dec. 2023 (ARS1,372,522 Mil).

Gilead Sciences Current Accrued Expense Historical Data

The historical data trend for Gilead Sciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Current Accrued Expense Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

330,189.37

467,690.84

749,749.75

583,254.33

1,372,522.00

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															583,254.33	1,052,546.43	838,559.99	1,299,714.34	1,372,522.00

Gilead Sciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Gilead Sciences Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BUE:GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.